We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Expands Celgene’s Abraxane For Late-Stage Pancreatic Cancer
FDA Expands Celgene’s Abraxane For Late-Stage Pancreatic Cancer
September 13, 2013
The FDA Sept. 6 approved a new indication for Celgene’s Abraxane to treat patients with late-stage pancreatic cancer, an outcome prompted under priority review and orphan drug programs.